NEW YORK, March 20, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on PTLA, PLX, RDUS, and RGLS which can be accessed for free by signing up to www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com revisits the Biotech sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. Lined up for assessment this morning are: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), and Regulus Therapeutics Inc. (NASDAQ: RGLS). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Portola Pharmaceuticals
On Monday, shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. recorded a trading volume of 1.48 million shares, which was above their three months average volume of 1.30 million shares. The stock ended at $33.41, dropping 4.08% from the last trading session. The Company's shares are trading below their 50-day moving average by 27.03%. Furthermore, shares of Portola Pharma, which develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation, have a Relative Strength Index (RSI) of 31.35.
On March 01st, 2018, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'.
On March 12th, 2018, Portola Pharma announced the appointment of John B. Moriarty, J.D. as Executive Vice President and General Counsel, effective immediately. Mr. Moriarty will report to William Lis, CEO, and will serve as the Company's Chief Legal Officer, responsible for leading all legal, regulatory, governance, and compliance initiatives. He also will be directly involved in strategic business transactions and corporate expansion as a member of the Company's Executive Committee. Get the full research report on PTLA for free by clicking below at:
www.wallstequities.com/registration/?symbol=PTLA
Protalix BioTherapeutics
Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock finished yesterday's session 0.63% higher at $0.59. A total volume of 1.43 million shares was traded, which was above their three months average volume of 906,670 shares. The Company's shares are trading below their 50-day moving average by 12.21%. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 36.67.
On March 15th, 2018, Protalix BioTherapeutics announced that Moshe Manor, President and CEO will present a corporate overview at BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference on March 23rd, 2018, at 8:30 a.m. ET at the Millennium Broadway Hotel in New York City. A live and archived webcast of the presentation will be available under the event calendar page of the Company's website. The free technical report on PLX can be accessed at:
www.wallstequities.com/registration/?symbol=PLX
Radius Health
On Monday, shares in Waltham, Massachusetts headquartered Radius Health Inc. saw a decline of 2.09%, ending the day at $35.18. The stock recorded a trading volume of 792,655 shares. The Company's shares have advanced 22.75% in the previous three months. The stock is trading 3.03% below its 200-day moving average. Moreover, shares of Radius Health, which develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology, have an RSI of 47.09.
On March 01st, 2018, Radius Health reported its results for the fourth quarter and full year ended December 31st, 2017. For Q4 2017, net loss was $(71.0) million; TYMLOS net product revenues were $7.7 million; and research and development (R&D) expense was $22.9 million. For the full year, net loss was $(254.2) million; TYMLOS net product revenues were $12.1 million; and R&D expense was $83.1 million. Sign up for free on Wall St. Equities and claim the latest report on RDUS at:
www.wallstequities.com/registration/?symbol=RDUS
Regulus Therapeutics
San Diego, California headquartered Regulus Therapeutics Inc.'s shares ended the day 1.99% lower at $0.82 with a total trading volume of 428,843 shares. The stock is trading 24.69% below its 200-day moving average. Shares of the Company, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 31.59.
On March 07th, 2018, Regulus Therapeutics reported its Q4 and full-year 2017 results. For Q4 2017, revenue was less than $0.1 million, and net loss was $(14.4) million. For the full year, revenue was less than $0.1 million, and net loss was $(71.9) million. As of December 31st, 2017, the Company had cash, cash equivalents, and short-term investments of $60.1 million. See the free research coverage on RGLS at:
www.wallstequities.com/registration/?symbol=RGLS
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
www.wallstequities.com/registration
Portola Pharmaceuticals
On Monday, shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. recorded a trading volume of 1.48 million shares, which was above their three months average volume of 1.30 million shares. The stock ended at $33.41, dropping 4.08% from the last trading session. The Company's shares are trading below their 50-day moving average by 27.03%. Furthermore, shares of Portola Pharma, which develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation, have a Relative Strength Index (RSI) of 31.35.
Advertisement
On March 01st, 2018, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'.
On March 12th, 2018, Portola Pharma announced the appointment of John B. Moriarty, J.D. as Executive Vice President and General Counsel, effective immediately. Mr. Moriarty will report to William Lis, CEO, and will serve as the Company's Chief Legal Officer, responsible for leading all legal, regulatory, governance, and compliance initiatives. He also will be directly involved in strategic business transactions and corporate expansion as a member of the Company's Executive Committee. Get the full research report on PTLA for free by clicking below at:
www.wallstequities.com/registration/?symbol=PTLA
Protalix BioTherapeutics
Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock finished yesterday's session 0.63% higher at $0.59. A total volume of 1.43 million shares was traded, which was above their three months average volume of 906,670 shares. The Company's shares are trading below their 50-day moving average by 12.21%. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 36.67.
On March 15th, 2018, Protalix BioTherapeutics announced that Moshe Manor, President and CEO will present a corporate overview at BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference on March 23rd, 2018, at 8:30 a.m. ET at the Millennium Broadway Hotel in New York City. A live and archived webcast of the presentation will be available under the event calendar page of the Company's website. The free technical report on PLX can be accessed at:
www.wallstequities.com/registration/?symbol=PLX
Radius Health
On Monday, shares in Waltham, Massachusetts headquartered Radius Health Inc. saw a decline of 2.09%, ending the day at $35.18. The stock recorded a trading volume of 792,655 shares. The Company's shares have advanced 22.75% in the previous three months. The stock is trading 3.03% below its 200-day moving average. Moreover, shares of Radius Health, which develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology, have an RSI of 47.09.
On March 01st, 2018, Radius Health reported its results for the fourth quarter and full year ended December 31st, 2017. For Q4 2017, net loss was $(71.0) million; TYMLOS net product revenues were $7.7 million; and research and development (R&D) expense was $22.9 million. For the full year, net loss was $(254.2) million; TYMLOS net product revenues were $12.1 million; and R&D expense was $83.1 million. Sign up for free on Wall St. Equities and claim the latest report on RDUS at:
www.wallstequities.com/registration/?symbol=RDUS
Regulus Therapeutics
San Diego, California headquartered Regulus Therapeutics Inc.'s shares ended the day 1.99% lower at $0.82 with a total trading volume of 428,843 shares. The stock is trading 24.69% below its 200-day moving average. Shares of the Company, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 31.59.
On March 07th, 2018, Regulus Therapeutics reported its Q4 and full-year 2017 results. For Q4 2017, revenue was less than $0.1 million, and net loss was $(14.4) million. For the full year, revenue was less than $0.1 million, and net loss was $(71.9) million. As of December 31st, 2017, the Company had cash, cash equivalents, and short-term investments of $60.1 million. See the free research coverage on RGLS at:
www.wallstequities.com/registration/?symbol=RGLS
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----portola-pharma-protalix-biotherapeutics-radius-health-and-regulus-therapeutics-300616514.html
SOURCE Wall St. Equities
